Leadership Overview
Lilly has 10 executives leading key functions including strategy, financial oversight, commercial oncology, information technology, marketing, and operational management.
Committed to advancing medical science, Lilly delivers life-changing prescription medicines to patients worldwide through rigorous research and development in diabetes, oncology, immunology, and neuroscience.
Committed to advancing medical science, Lilly delivers life-changing prescription medicines to patients worldwide through rigorous research and development in diabetes, oncology, immunology, and neuroscience.
Leadership Roles at Lilly
Susan Kurkowski - Chief Executive Officer & Assistant
Susan Kurkowski, the Chief Executive Officer & Assistant at Lilly, directs the overarching strategic vision and administrative alignment of the organization. Kurkowski manages high-level corporate governance while ensuring that internal support structures facilitate the discovery and commercialization of prescription medicines. By coordinating executive workflows, the Chief Executive Officer & Assistant optimizes decision-making processes across the global biopharmaceutical landscape. This leadership role involves maintaining rigorous standards in research-driven innovation to address complex health challenges in diabetes and neuroscience. Susan Kurkowski monitors the integration of administrative efficiency with long-term corporate objectives, ensuring that the firm maintains a competitive edge in international markets. Through precise oversight of organizational resources, the Chief Executive Officer & Assistant drives the company toward sustainable growth and improved patient outcomes, reinforcing the commitment to medical excellence and scientific advancement.
Dima Glikman - Chief Financial Officer, Cluster (Israel)
Dima Glikman, the Chief Financial Officer, Cluster (Israel) at Lilly, manages the fiscal health and economic strategy for regional operations. Glikman oversees capital allocation, financial reporting, and budgetary compliance to support the development of innovative pharmaceutical solutions. By analyzing market trends within the Middle Eastern sector, the Chief Financial Officer, Cluster (Israel) ensures that resource distribution aligns with the broader corporate mission of delivering life-changing medicines. This role requires constant collaboration with global finance teams to mitigate economic risks and capitalize on emerging opportunities in immunology and oncology. Dima Glikman drives financial transparency and operational efficiency, providing the necessary data to inform strategic investments. Through disciplined fiscal management, the Chief Financial Officer, Cluster (Israel) secures the financial stability required to sustain the company's research-intensive business model and expand the reach of essential therapies to diverse patient populations.
Peter Hoogerhuis - Global Chief Financial Officer, Commercial Oncology BU (Ed)
Peter Hoogerhuis, the Global Chief Financial Officer, Commercial Oncology BU (Ed) at Lilly, directs the financial architecture for the oncology business unit. Hoogerhuis manages revenue forecasting, cost structures, and investment strategies specifically tailored to the development and commercialization of cancer treatments. By evaluating the profitability of clinical pipelines, the Global Chief Financial Officer, Commercial Oncology BU (Ed) ensures that capital flows toward high-impact research initiatives. This leadership position involves close coordination with global commercial teams to maximize market penetration and therapeutic access. Peter Hoogerhuis drives financial accountability across the oncology portfolio, balancing the high costs of drug development with the necessity of delivering affordable, life-saving solutions. Through rigorous financial modeling and strategic oversight, the Global Chief Financial Officer, Commercial Oncology BU (Ed) supports the company's mission to transform cancer care, ensuring that the business unit remains both scientifically innovative and economically robust.
Julie Deranick - Chief Operating Officer, Portfolio & Project Management
Julie Deranick, the Chief Operating Officer, Portfolio & Project Management at Lilly, directs the execution of the company's diverse drug development pipeline. Deranick oversees the prioritization of research projects, ensuring that resources are allocated to the most promising therapeutic candidates in immunology and neuroscience. By implementing standardized project management frameworks, the Chief Operating Officer, Portfolio & Project Management optimizes the speed and efficiency of clinical trials. This role involves coordinating with research and development teams to navigate complex regulatory landscapes and meet critical development milestones. Julie Deranick drives operational excellence by identifying bottlenecks and streamlining workflows across the portfolio. Through rigorous oversight of project timelines and deliverables, the Chief Operating Officer, Portfolio & Project Management ensures that the company maintains a steady flow of innovative medicines, ultimately supporting the firm's mission to improve patient health through scientific discovery and disciplined operational execution.
Kevin Duffin - Vice President, Chief Operating Officer, and Head of Core Technologies
Kevin Duffin, the Vice President, Chief Operating Officer, and Head of Core Technologies at Lilly, directs the technological infrastructure and operational systems that underpin the company's manufacturing and research capabilities. Duffin oversees the implementation of advanced manufacturing technologies and digital platforms to enhance production efficiency and product quality. By integrating core technologies into the drug development lifecycle, the Vice President, Chief Operating Officer, and Head of Core Technologies ensures that the firm remains at the forefront of biopharmaceutical innovation. This leadership role involves managing large-scale technical operations and fostering collaboration between engineering and scientific teams. Kevin Duffin drives the adoption of scalable solutions that support the global commercialization of prescription medicines. Through strategic oversight of technical assets, the Vice President, Chief Operating Officer, and Head of Core Technologies enables the company to maintain high standards of manufacturing excellence, ensuring that life-saving therapies reach patients with consistency and reliability.
Amanda McDaniel - Associate Vice President & Chief Operating Officer, Early Phase Portfolio Project Management
Amanda McDaniel, the Associate Vice President & Chief Operating Officer, Early Phase Portfolio Project Management at Lilly, directs the operational strategy for the initial stages of drug discovery and development. McDaniel oversees the transition of research concepts into clinical trials, ensuring that early-phase projects adhere to strict scientific and operational standards. By managing the complexities of the early-stage pipeline, the Associate Vice President & Chief Operating Officer, Early Phase Portfolio Project Management facilitates the rapid assessment of new therapeutic targets in oncology and immunology. This role involves coordinating with research scientists and clinical teams to optimize study designs and resource allocation. Amanda McDaniel drives the efficiency of the early-phase portfolio, ensuring that the most viable candidates advance toward later development stages. Through meticulous project management and strategic oversight, the Associate Vice President & Chief Operating Officer, Early Phase Portfolio Project Management supports the company's commitment to pioneering new medical solutions for patients worldwide.
Wayne Russo - LoxoLilly Field Chief Operating Officer
Wayne Russo, the LoxoLilly Field Chief Operating Officer at Lilly, directs the field-based operational strategies for the LoxoLilly oncology division. Russo oversees the deployment of commercial resources and clinical support teams to ensure that specialized cancer therapies reach the intended patient populations effectively. By managing field operations, the LoxoLilly Field Chief Operating Officer ensures that healthcare providers receive the necessary information and support to utilize the company's oncology portfolio. This role involves coordinating with regional sales and medical affairs teams to drive market adoption and improve patient access to innovative treatments. Wayne Russo executes operational plans that align with the company's broader oncology strategy, focusing on delivering high-quality care in complex clinical environments. Through active field leadership, the LoxoLilly Field Chief Operating Officer optimizes the delivery of specialized medicines, ensuring that the firm's research-driven oncology solutions make a meaningful impact on patient outcomes across diverse clinical settings.
LisaAnn Trembath - Chief Operating Officer, Global Imaging
LisaAnn Trembath, the Chief Operating Officer, Global Imaging at Lilly, directs the operational strategy for the company's global imaging initiatives. Trembath oversees the integration of diagnostic imaging technologies into the drug development and clinical trial processes, enhancing the ability to monitor therapeutic efficacy in areas like neuroscience and oncology. By managing the global imaging portfolio, the Chief Operating Officer, Global Imaging ensures that advanced diagnostic tools are utilized to support precision medicine and patient-centric research. This role involves coordinating with global research teams to standardize imaging protocols and data analysis across international markets. LisaAnn Trembath drives operational efficiency by streamlining the use of imaging assets and ensuring compliance with global regulatory standards. Through strategic oversight of imaging operations, the Chief Operating Officer, Global Imaging supports the company's mission to deliver innovative therapies, providing the critical data needed to validate the impact of new medicines on patient health.
Tracy Huang - Senior Secretary To Chief Information Officer
Tracy Huang, the Senior Secretary To Chief Information Officer at Lilly, coordinates the operational flow and communication strategies within the information technology department. Huang manages complex scheduling, departmental documentation, and cross-functional logistics to ensure that the Chief Information Officer maintains focus on digital transformation and data security. By facilitating seamless interactions between IT leadership and other business units, the Senior Secretary To Chief Information Officer supports the integration of advanced technology into the drug discovery and manufacturing processes. This role involves organizing critical meetings and managing information streams that drive the company's technological infrastructure. Tracy Huang ensures that the Chief Information Officer has the necessary administrative support to oversee global digital initiatives effectively. Through meticulous attention to detail and organizational management, the Senior Secretary To Chief Information Officer contributes to the efficiency of the firm's research-driven innovation, enabling the seamless deployment of digital tools across the enterprise.
Gareth Richmond - Associate Vice President & Chief Marketing Officer & Director, Cardio Metabolic Health Business, Anz
Gareth Richmond, the Associate Vice President & Chief Marketing Officer & Director, Cardio Metabolic Health Business, Anz at Lilly, directs the commercial strategy and brand positioning for cardio-metabolic therapies within the Australian and New Zealand markets. Richmond oversees market access, product launches, and customer engagement initiatives to ensure that patients receive timely access to essential treatments. By analyzing regional health trends, the Associate Vice President & Chief Marketing Officer & Director, Cardio Metabolic Health Business, Anz aligns marketing efforts with the company's global focus on diabetes and metabolic health. This leadership role involves managing cross-functional teams to drive product adoption and strengthen the firm's market presence. Gareth Richmond executes strategic campaigns that highlight the clinical value of the company's portfolio. Through effective market leadership, the Associate Vice President & Chief Marketing Officer & Director, Cardio Metabolic Health Business, Anz ensures that the organization remains a trusted partner in the healthcare ecosystem, consistently delivering value to patients and providers.
Explore Leadership Teams in Manufacturing
Biogen is a U.S.-based biotechnology company focused on discovering, developing, and commercializing therapies for serious neurological and neurodegenerative diseases. Its core portfolio includes treatments for conditions such as multiple sclerosis, spinal muscular atrophy, and other rare neurological disorders, supported by advanced research in neuroscience, biologics, and gene-based therapies.
Company Leadership

ER

Bausch Health Companies Inc. operates as a global pharmaceutical and healthcare products company focused on developing, manufacturing, and marketing a broad portfolio of branded pharmaceuticals, generic medicines, over-the-counter healthcare products, and medical devices. The organization works to improve patient health outcomes by delivering therapeutic solutions across multiple medical specialties. Through its research, development, and commercial operations, the company serves healthcare providers, hospitals, pharmacies, and patients across numerous international markets. The company functions as a diversified healthcare enterprise with business segments that address several therapeutic and medical device categories. Its core focus areas include gastroenterology, hepatology, neurology, dermatology, dentistry, medical aesthetics, and ophthalmology. By maintaining a broad therapeutic portfolio, the organization supports healthcare professionals in diagnosing, managing, and treating a wide range of medical conditions that affect millions of patients globally.
Company Leadership
MM
Founded in 1958 and headquartered in Chatswood, Australia, iNova Pharmaceuticals is an international organization that develops, markets, and sells a wide-range of prescription medicines and non-prescription consumer health products across Asia, Australia and New Zealand, and Africa.
Company Leadership YG
PS
AJ
SE
Divis Laboratories Limited is a leading manufacturer of Active Pharmaceutical Ingredients (APIs) based in Hyderabad, India, recognized as one of the top three API manufacturers globally. The company specializes in Generic APIs, Custom Synthesis, and Nutraceuticals, serving over 100 countries and providing high-quality products to major pharmaceutical companies. With a commitment to quality and sustainability, Divis operates extensive manufacturing facilities and R&D centers, employing over 2,500 analysts to ensure compliance with stringent global standards. Their diverse portfolio includes a wide range of carotenoids and vitamins, catering to the nutritional, pharmaceutical, and food industries.
Company Leadership

KL
MJ